Amwill Healthcare IPO booked over 5 times on last day: Check subscription, allotment status and listing date

Derma products maker and distributor Amwill Healthcare Ltd’s initial public offering (IPO) garnered strong interest among the investors on the last day of bidding on Friday, February 7. The BSE SME issue was booked more than 5 times on the first day of bidding.

The ₹59.98-crore public offer attracted applications for over 2.96 lakh shares against 54.03 lakh shares on offer, leading to an overall subscription of 5.49 times.

The retail investors placed applications for more than 97.89 lakh shares against 20.53 lakh shares on offer. The retail portion was booked 4.77 times. The Non-Institutional Investors (NIIs) submitted applications for 1.18 crore shares against 23.24 lakh shares on offer, leading to a subscription of 5.12 times in the segment. The Qualified Institutional Buyers (QIBs) placed bids for more than 80.01 lakh shares against 10.26 lakh shares on offer. The QIBs booked their quota 7.8 times.

The IPO was open for subscription from February 5 to February 7. The investors are now looking forward to the share allotment status being finalised by the company.

Amwill Healthcare Ltd is expected to announce the IPO share allotment status on Monday, February 10. The investors, who participated in the IPO bidding, can check the share allotment status on the BSE and issue registrar, Bigshare Services Pvt Ltd.

How to check status on IPO registrar’s website:

• Visit Bigshare Services Pvt Ltd website at https://www.bigshareonline.com
• Click on the IPO allotment status link
• On the new page select any server from the 3 links
• Select Amwill Healthcare Ltd from the list of company names
• Choose any of these: Application number, Beneficiary ID and PAN
• Complete the 'captcha' for verification
• Click the "Search" button to check the allotment status

Steps to check IPO allotment status on the BSE website:

• Go to the BSE IPO allotment status page: https://www.bseindia.com/investors/appli_check.aspx
• Choose ‘equity’ as the issue type
• Select Amwill Healthcare Ltd from the list of issue names
• Enter PAN details or application number
• Submit to check the details

Amwill Healthcare Limited IPO details

Amwill Healthcare is engaged in the business of derma-cosmetic products. The company develops and distributes dermatological, cosmeceutical and aesthetical products. It engages with contract manufacturers, distributors and third-party product development agencies to develop, produce, package and distribute products.

The company has a presence primarily in three states of Telangana Karnataka and Andhra Pradesh.

• Amwill Healthcare IPO comprises a fresh issue of 44.04 lakh shares, amounting to ₹48.88 crore, and an offer-for-sale (OFS) of 10 lakh shares, worth ₹11.1 crore.
• The IPO price was fixed at ₹105 to ₹111 per share.
• The lot size is 1,200 shares, requiring a minimum investment of ₹1,33,200.
• The company will initiate refunds and transfer of shares to the Demat accounts on February 11.
• Amwill Healthcare has proposed to list its shares on February 12
• Shares of the company will be listed on the BSE SME platform.

Amwill Healthcare IPO Objects

According to Amwill Healthcare RHP, the company would utilise the IPO funds from the fresh issue to fund working capital needs and meet marketing and promotion expenses.

It has proposed to use ₹25 crore for working capital requirements and a sum of ₹5 crore for funding marketing and brand-building expenditure.

Proceeds from the OFS part will go to selling shareholders – promoters Bhavika Gandhi and Isha Gandhi and two other promoters.

Amwill Healthcare financials

Amwill Healthcare reported a net profit of ₹6.51 crore for the April-September period of 2024-25. Its total income stood at ₹23.24 crore for the period.

The derma products company reported a net profit of ₹12.53 crore in FY24 compared to ₹3.11 crore in FY23. Its total income stood at ₹44.28 crore in FY24 against ₹30.28 crore in the preceding financial year.

Amwill Healthcare Key Performance Indicators (for FY 2023-24)